BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes

Core Insights - BioPorto A/S has successfully completed a private placement, raising approximately DKK 43 million through the issuance of 40,438,426 new shares, which represents 8.89% of the company's registered share capital prior to the increase [1][2]. Group 1: Share Capital Increase - The capital increase has been registered with the Danish Business Authority, and the gross proceeds from the issue amount to approximately DKK 43 million [2]. - The new shares will carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3]. Group 2: Company Overview - BioPorto is focused on in vitro diagnostics, particularly in developing kidney biomarkers to aid in the management of Acute Kidney Injury (AKI) [5]. - The company's flagship products utilize the NGAL biomarker, which allows for quicker identification of patients at risk of AKI, facilitating earlier intervention [5]. - BioPorto's shares are listed on the Nasdaq Copenhagen stock exchange, and the company has facilities in both Copenhagen, Denmark, and Boston, MA, USA [6].